Drug intelligence / Profile preview

26ND01

Development stage: Preclinical
Lead developer: HK inno.N Corporation
Modality: Small Molecules

Overview

26ND01 is a discovery-stage small molecule drug candidate being developed by HK inno.N for the treatment of obesity. As of early 2026, the program is in the discovery phase of development. Specific details regarding its biological target or mechanism of action have not been publicly disclosed by the company, but it represents part of HK inno.N's expanding metabolic disease pipeline alongside other obesity-focused candidates like 24ND03 and 25ND01.

Beyond the preview

Go deeper on 26ND01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 26ND01.

Explore the full profile